Kentucky House Bill 229

---

Spectrum: Partisan Bill (Republican 6-0)
Status: Introduced on January 10 2024 - 25% progression
Action: 2024-01-10 - to Committee on Committees (H)
Pending: House Committee On Committees Committee
Text: Latest bill text (Introduced) [PDF]

Create a new section of KRS 217.005 to 217.215, the Kentucky Food, Drug, and Cosmetic Act, to define terms; require products that are known to be or could act as gene therapy to be labeled with the words "Potential Gene Therapy Product" or "Gene Therapy Product"; require any entity in the state that produces, sells, or distributes a product in this state with the capacity to infect an individual with a disease or to expose an individual with genetically modified material to provide information upon request on how individuals may be exposed; require informed consent before any entity makes available a product in this state that would act as a medical intervention, vaccine, drug, or genetic modification.

AN ACT relating to gene therapy.

Rep. Emily Callaway [R]	Rep. Jennifer Henson Decker [R]	Rep. Danny Bentley [R]	Rep. John Hodgson [R]
Rep. Marianne Proctor [R]	Rep. Steve Rawlings [R]

Date	Chamber	Action
2024-01-10	House	to Committee on Committees (H)
2024-01-10	House	introduced in House

Type	Source
Summary	https://apps.legislature.ky.gov/record/24RS/hb229.html
Text	https://apps.legislature.ky.gov/recorddocuments/bill/24RS/hb229/orig_bill.pdf